These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28592703)

  • 1. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
    Aggarwal R; Behr SC; Paris PL; Truillet C; Parker MFL; Huynh LT; Wei J; Hann B; Youngren J; Huang J; Premasekharan G; Ranatunga N; Chang E; Gao KT; Ryan CJ; Small EJ; Evans MJ
    Mol Cancer Res; 2017 Sep; 15(9):1221-1229. PubMed ID: 28592703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Feasibility Study Showing [
    Behr SC; Aggarwal R; Seo Y; Aparici CM; Chang E; Gao KT; Tao DH; Small EJ; Evans MJ
    Mol Imaging Biol; 2016 Dec; 18(6):946-951. PubMed ID: 27184068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annotating MYC status with 89Zr-transferrin imaging.
    Holland JP; Evans MJ; Rice SL; Wongvipat J; Sawyers CL; Lewis JS
    Nat Med; 2012 Oct; 18(10):1586-91. PubMed ID: 23001181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.
    Doran MG; Carnazza KE; Steckler JM; Spratt DE; Truillet C; Wongvipat J; Sawyers CL; Lewis JS; Evans MJ
    Mol Pharm; 2016 Feb; 13(2):683-8. PubMed ID: 26725682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation.
    Kumar V; Boddeti DK
    Recent Results Cancer Res; 2013; 194():189-219. PubMed ID: 22918761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Hepatocellular Carcinoma With
    Mari Aparici C; Behr SC; Seo Y; Kelley RK; Corvera C; Gao KT; Aggarwal R; Evans MJ
    Mol Imaging; 2017; 16():1536012117723256. PubMed ID: 28893116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.
    Reiter RE; Sato I; Thomas G; Qian J; Gu Z; Watabe T; Loda M; Jenkins RB
    Genes Chromosomes Cancer; 2000 Jan; 27(1):95-103. PubMed ID: 10564591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
    Maurer T; Gschwend JE; Rauscher I; Souvatzoglou M; Haller B; Weirich G; Wester HJ; Heck M; Kübler H; Beer AJ; Schwaiger M; Eiber M
    J Urol; 2016 May; 195(5):1436-1443. PubMed ID: 26682756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study between
    Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH
    J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of new target CDK19 in prostate cancer.
    Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity, Specificity, and Predictors of Positive
    Perera M; Papa N; Christidis D; Wetherell D; Hofman MS; Murphy DG; Bolton D; Lawrentschuk N
    Eur Urol; 2016 Dec; 70(6):926-937. PubMed ID: 27363387
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR.
    Behr SC; Villanueva-Meyer JE; Li Y; Wang YH; Wei J; Moroz A; Lee JK; Hsiao JC; Gao KT; Ma W; Cha S; Wilson DM; Seo Y; Nelson SJ; Chang SM; Evans MJ
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.